Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)

NCT06564324 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT06564324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06564324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
November 27, 2024
Completion date
September 30, 2030
Enrollment
194 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer